TCT 2024 Late-Breaking Science Collection
Published: 17 October 2024
-
Views:
2697
-
Likes:
7
-
Views:
2697
-
Likes:
7
-
6m 24sPart 3 | Session 1 5 Trials That Will Change My Practice with Dr Mirvat Alasnag -
5m 1sPart 3 | Session 2 2 Trials That Will Change My Practice with Dr Sahil Parikh
-
38m 7sPart 1 View from the Thoraxcenter: TCT 24 Late-breaking Preview Nicolas M Van Mieghem, Joost Daemen
-
7m 10sPart 2 | Session 1 SIRONA: Sirolimus- vs. Paclitaxel-Coated Balloon Angioplasty in the Femoropopliteal Artery Ulf Teichgräber
-
4m 10sPart 2 | Session 2 TAVR UNLOAD: Transcatheter Aortic Valve Replacement in Patients with Heart Failure and Moderate Aortic Stenosis Nicolas M Van Mieghem
-
4m 19sPart 2 | Session 3 EVOLVED: Early Intervention in Patients with Asymptomatic Severe Aortic Stenosis and Left Ventricular Decompensation Marc Dweck
-
5m 36sPart 2 | Session 4 MATTERHORN: Transcatheter Repair Versus Surgery in Mitral Regurgitation Stephan Baldus
-
3m 34sPart 2 | Session 5 INFINITY-SWEDEHEART: DynamX Bioadaptor in Patients with Complex Lesions David Erlinge
-
3m 43sPart 2 | Session 6 Pooled Analysis of the RHEIA and PARTNER 3 Trials: Transcatheter vs. Surgical Aortic Valve Replacement in Women Didier Tchétché
-
3m 33sPart 2 | Session 7 CLASP IID: Two-Year Outcomes of Transcatheter Edge-to-Edge Repair for Degenerative Mitral Regurgitation Firas Zahr
-
3m 56sPart 2 | Session 8 ECLIPSE: Orbital Atherectomy vs. Conventional Balloon Angioplasty in Calcified Coronary Arteries Prior to DES Implantation Ajay J Kirtane
Overview
Keep informed with our video collection unveiling data from the Transcatheter Cardiovascular Therapeutics Conference in Washington. With expert insights on late-breaking trials and critical findings, you won't want to miss our #TCT24 coverage.
- For practice-focused reviews of the most anticipated trials, watch our recurring View From the Thoraxcenter series, hosted by Prof Nicolas Van Mieghem and Dr Joost Daemen (Thoraxcenter, Erasmus MC, Rotterdam, NL).
- Our short Expert Interviews with select faculty offer focused data analysis and take-home messages for practice.
- To delve deeper into insights on the most pertinent trials, catch our Highlights.
Dive into the latest cardiology research with our upcoming TCT Conference coverage.
More from this programme
Part 1
View From the Thoraxcenter: What's Hot at TCT 24?
Part 2
Expert Interviews
About the episode
TCT Conference 2024 - Safety and efficacy outcomes of transcatheter tricuspid valve replacement (TTVR) compared to optimal medical therapy for patients with severe tricuspid regurgitation (TR).
Dr Susheel Kodali (Columbia University Medical Center, New York, US) joins us onsite at TCT Conference to discuss the findings from the TRISCEND II Trial (NCT04482062; Edwards Lifesciences).
TRISCEND II is a multi-center, prospective, randomized trial designed to evaluate the safety and effectiveness of the Edwards EVOQUE tricuspid valve replacement system as compared to optimal medical therapy alone in patients with severe TR. 1,070 patients were enrolled in the trial and were followed-up at 30 days, 3 months, 6 months, and annually for five years post treatment. The primary outcome measures included TR grade reduction, including KCCQ improvement, NYHA functional class improvement and 6-minute walk test distance improvement, as well as a composite endpoint including all-cause mortality, RVAD implantation or heart transplant, tricuspid valve intervention and heart failure hospitalisations.
One year findings showed that the Edwards EVOQUE system demonstrated superiority in primary endpoints for a patient population with limited treatment options. The Edwards EVOQUE system also led to sustained TR reduction with significant improvements in symptoms, function, and quality of life at one year.
Interview Questions:
1. What is the reasoning behind the TRISCEND II trial?
2. What was the study design and patient population?
3. What were the key findings?
4. Were there any surprising or unexpected results?
5. What further study is needed?
Recorded at TCT Conference in Washington, 2024.
Editors: Yazmin Sadik, Jordan Rance
Video Specialist: David Ben-Harosh, Oliver Miles
Support: This is an independent interview produced by Radcliffe Cardiology.
Faculty Biographies
Susheel Kodali
Director of the Structural Heart and Valve Center and Professor in medicine
Dr Susheel Kodali is the Director of the Structural Heart and Valve Center and a Professor in Medicine at Columbia University Medical Center. Dr Kodali attended medical school at UCLA before completing two fellowships in clinical and interventional cardiology at the UCSF Medical Centre and Columbia University Irving Medical Center.
Dr. Kodali specialises in the percutaneous treatment of coronary artery and structural heart disease, including angioplasty and TAVR. He also serves as co-investigator of the PARTNER trials and is part of the trial steering committee.
Comments